John Mulligan, Good Therapeutics CEO
Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin
There’s Just, and there’s Good.
The first was sold in summer 2019. And the PD-1 IL-2 portion of the latter is now entering the fold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
